title: A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer.
abstract: Long-term survival in epithelial ovarian cancer remains problematic despite multimodality therapy. A fundamental difficulty is the development of tumor resistance to platinum compounds. Analogs have been developed that demonstrate activity in platinum-resistant cell lines both in vitro and in vivo. Lobaplatin (D-19466), a third-generation compound, demonstrates significant activity in carboplatin and cisplatin-resistant cell lines. Lobaplatin was given to 17 assessable patients with platinum-refractory ovarian cancer. The drug was initially administered at a dose of 50 mg/m2 but was later reduced to 40 mg/m2 because of excessive thrombocytopenia. Nine patients required red cell transfusions during therapy. Cycles were repeated every 21-35 days (median cycle length 28 days). No objective responses were observed. Lobaplatin has no activity in platinum-resistant epithelial ovarian cancer.
authors.affiliation: Section of Gynecologic Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
authors.forename: J J
authors.initials: JJ
authors.lastname: Kavanagh
authors.forename: C L
authors.initials: CL
authors.lastname: Edwards
authors.forename: R S
authors.initials: RS
authors.lastname: Freedman
authors.forename: M B
authors.initials: MB
authors.lastname: Finnegan
authors.forename: O
authors.initials: O
authors.lastname: Balat
authors.forename: D
authors.initials: D
authors.lastname: Tresukosol
authors.forename: K
authors.initials: K
authors.lastname: Burk
authors.forename: S
authors.initials: S
authors.lastname: Loechner
authors.forename: M
authors.initials: M
authors.lastname: Hord
authors.forename: J L
authors.initials: JL
authors.lastname: Franklin
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003503:Cyclobutanes / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010984:Platinum / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D003503:Cyclobutanes; D009944:Organoplatinum Compounds; D010984:Platinum; C066228:lobaplatin